Using China’s Innovative Device Pathway; CFDA’s Yongheng Chang to address Asia Pacific Device Summit
We are delighted to confirm that the forthcoming Asia Pacific Device Summit will feature a presentation by Yongheng Chang of China Food and Drug Administration.
Mr Chang will speak on China’s Policies to support Medical Device Innovation including navigating the Innovative Device Pathway for CFDA approval, He will also provide an up to the minute update on CFDA regulatory changes.
The Asia Pacific Device Summit provides a two day deep dive into current regulatory requirements, policies and challenges across the Asia Pacific.
We bring Asia to you. Hear direct from leading experts from China, SE Asia, Australia, India and more. Attendance is limited to ensure an intimate forum for in-depth discussion and learning.
APDS is on March 19-20, 2018 Yorba Linda, California.
Attendees earn 11 Continuing Education Credits for RAPS RAC certification.
Click here to register now
Chang Yongheng is Executive Chairman of the China International Medical Device Regulatory Forum (CIMDR) – the world’s largest medical device regulatory conference, and past Deputy Director of CFDA’s China Center for Food and Drug International Exchange (CCFDIE). His career started with 11 years in medical device and pharmaceutical manufacturing. He has since served in multiple senior roles in the Chinese government sector, including Deputy Division Director in the Department of International Cooperation of SPAC (State Pharmaceutical Administration of China), Director of Foreign Medical Device Registrations of SPAC, Director of the Medical Device Registration of SFDA (State Food and Drug Administration), Deputy Counsel of the Department of Medical Devices of SFDA, and Deputy Director General of CCFDIE. Mr Chang is currently Deputy Director of the Committee for Research of Medical Device Regulation of the China Society for Drug Regulation (CSDR), Deputy Director of the Committee for Research of International Exchange and Cooperation of CSDR, and a Senior Member of the Chinese Pharmaceutical Association.
We offer comprehensive support including an outsourced review of marketing and labelling content. Contact us for a free, no obligation discussion.
Email [email protected] or call: 1 888-271-5063 (US toll free) ♦ 400-842 7017 (Beijing – toll free) ♦ +61 2 9906 2984 (Sydney)